Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Ticker
$EOLS
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
372
ISIN
US30052C1071
Website
Evolus Metrics
BasicAdvanced
$600M
-
-$0.89
1.00
-
Price and volume
Market cap
$600M
Beta
1
52-week high
$17.12
52-week low
$8.67
Average daily volume
1.2M
Financial strength
Current ratio
2.342
Quick ratio
2.051
Long term debt to equity
-1,941.763
Total debt to equity
-1,971.548
Interest coverage (TTM)
-1.78%
Profitability
EBITDA (TTM)
-27.462
Gross margin (TTM)
68.41%
Net profit margin (TTM)
-20.40%
Operating margin (TTM)
-11.95%
Effective tax rate (TTM)
-1.24%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
-9.36%
Return on equity (TTM)
-949.46%
Valuation
Price to revenue (TTM)
2.135
Price to book
-90.76
Price to tangible book (TTM)
-7.77
Price to free cash flow (TTM)
-20.349
Free cash flow yield (TTM)
-4.91%
Free cash flow per share (TTM)
-45.70%
Growth
Revenue change (TTM)
25.38%
Earnings per share change (TTM)
-14.84%
3-year revenue growth (CAGR)
31.43%
3-year earnings per share growth (CAGR)
-12.00%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Bulls say / Bears say
BTIG Research initiated coverage on Evolus with a 'buy' rating and a $21.00 target price, indicating confidence in the company's growth prospects. (etfdailynews.com)
Barclays raised its price target for Evolus from $22.00 to $25.00, maintaining an 'overweight' rating, reflecting a positive outlook on the stock. (etfdailynews.com)
Evolus reported a fourth-quarter profit, transitioning from a year-ago loss, driven by strong demand for its wrinkle treatment Jeuveau, suggesting robust product performance. (stockinvest.us)
In Q1 2025, Evolus reported a loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.10 loss, indicating financial underperformance. (finviz.com)
The company has a high debt-to-equity ratio of 20.58, which may pose financial risks and limit operational flexibility. (techdows.com)
Evolus' stock price declined by 9.21% on April 10, 2025, reflecting potential investor concerns or market volatility. (stockinvest.us)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Evolus News
AllArticlesVideos
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·7 days ago
Evolus Announces Departure of its Chief Financial Officer
Business Wire·3 weeks ago
Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $600M as of June 20, 2025.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of June 20, 2025.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.